Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ONWARD3

42 evidence topics · 5 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Secondary outcomes in the ClinicalTrials.gov record
Secondary outcome measureMeasure description and time frame
“To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-75)”“Proportion of patients achieving ≥75% reduction in PASI 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-90)”“Proportion of patients achieving ≥90% reduction in PASI 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-100)”“Proportion of patients achieving 100% reduction in PASI 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 using the Static Physician's Global Assessment (sPGA 0/1)”“Proportion of patients achieving a score of 0 or 1 on sPGA 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 based on change in Psoriasis Area and Severity Index (PASI)”“Change in Psoriasis Area and Severity Index (PASI) from baseline assessments 24, 48, 72, and 96 weeks”
“To assess the long-term efficacy of ESK-001 based on change in Affected Body Surface Area (%BSA)”“Change in affected body surface area (%BSA) from baseline assessments 24, 48, 72, and 96 weeks”
“To characterize the loss of PASI-75 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)”“Median time to loss of PASI-75 response Week 48”
“To characterize the loss of PASI-90 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)”“Median time to loss of PASI-90 response Week 48”
“To characterize the loss of sPGA-0/1 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)”“Median time to loss of sPGA-0/1 response Week 48”
“To assess the change in quality of life (QoL) using Dermatology Life Quality Index after long-term ESK-001 administration”“Proportion of patients achieving a DLQI-0/1 score of 0 (no effect) or 1 (minimal effect) Week 24, Week 48, and Week 72”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics at ONWARD3 entry by parent-study arm
CharacteristicEnvudeucitinib then envudeucitinib (n = 773)Placebo then envudeucitinib (n = 367)Apremilast then envudeucitinib (n = 369)
Envudeucitinib exposure at start of ONWARD3, weeks“24”“8”“0”
Age, years, mean (SD)“49.6 (13.2)”“50.6 (13.3)”“49.1 (12.4)”
Duration of disease, years, mean (SD)“20.2 (13.5)”“20.1 (13.8)”“19.0 (13.0)”
Prior systemic psoriasis treatment, n (%)“395 (51.1)”“185 (50.4)”“186 (50.4)”
PASI, mean (SD)“1.9 (3.6)”“4.5 (5.5)”“6.7 (7.0)”
ss-PGA ≥3, n (%)“18 (2.3)”“21 (5.7)”“58 (15.7)”
BSA % affected, mean (SD)“3.8 (7.7)”“9.4 (12.3)”“10.7 (13.2)”
Worst pruritus NRS score, mean (SD)“1.3 (1.9)”“2.0 (2.3)”“3.1 (2.8)”
DLQI, mean (SD)“1.8 (3.1)”“2.9 (3.8)”“4.0 (4.9)”
Efficacy results
Maintenance of skin and scalp response at 48 weeks among ONWARD1 and ONWARD2 responders
EndpointAchieved response at the end of ONWARD1 and 2, nMaintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI)
PASI 75“678”“89.8 (87.3, 92.0)”
PASI 90“575”“89.4 (86.6, 91.8)”
sPGA-0/1“584”“87.5 (84.5, 90.1)”
PASI 100“357”“80.1 (75.6, 84.1)”
sPGA-0“365”“79.5 (74.9, 83.5)”
ss-PGA-0/1, among patients with parent baseline ss-PGA ≥3“418”“89.5 (86.1, 92.2)”
Health-related quality of life and patient-reported outcomes
Maintenance of itch and DLQI response at 48 weeks among ONWARD1 and ONWARD2 responders
EndpointAchieved response at the end of ONWARD1 and 2, nMaintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI)
At least 4-point improvement from parent baseline in NRS worst pruritus, among patients with parent baseline NRS worst score ≥4“509”“86.2 (82.9, 89.1)”
DLQI-0/1, among patients with parent baseline DLQI ≥2“497”“86.3 (83.0, 89.2)”
Safety results
Adverse events with exposure-adjusted incidence rates by parent-study arm through week 48
EventEnvudeucitinib then envudeucitinib (n = 773), n (%)EAIRPlacebo then envudeucitinib (n = 367), n (%)EAIRApremilast then envudeucitinib (n = 369), n (%)EAIR
At least 1 TEAE“521 (67.4)”“177.9”“253 (68.9)”“185.4”“268 (72.6)”“219.2”
At least 1 SAE“25 (3.2)”“4.7”“16 (4.4)”“6.3”“9 (2.4)”“3.6”
TEAEs grade ≥3“45 (5.8)”“8.6”“31 (8.4)”“12.5”“16 (4.3)”“6.5”
TEAEs leading to discontinuation“23 (3.0)”“4.3”“11 (3.0)”“4.2”“25 (6.8)”“10.1”
Related TEAEs“104 (13.5)”“21”“52 (14.2)”“21.7”“82 (22.2)”“37.9”
Nasopharyngitis“109 (14.1)”“22.2”“67 (18.3)”“28.8”“44 (11.9)”“19”
Upper respiratory tract infection“92 (11.9)”“18.4”“44 (12.0)”“18.1”“44 (11.9)”“18.7”
Influenza“34 (4.4)”“6.5”“19 (5.2)”“7.5”“17 (4.6)”“6.9”
Urinary tract infection“37 (4.8)”“7.1”“9 (2.5)”“3.5”“13 (3.5)”“5.3”
Acne“14 (1.8)”“2.6”“9 (2.5)”“3.5”“18 (4.9)”“7.5”
Study limitations
Summary
  • Results of the randomized treatment withdrawal period, which began after 24 weeks for the first 200 participants, are “data not reported” in the congress poster.
  • All participants received open-label envudeucitinib during the first 24 weeks, with no concurrent control group; regulatory guidance states that the absence of a concurrent control group makes it more difficult to assess the causality relationship between adverse events and the drug.
  • Entry required completion of week 24 of a parent trial, consent, and acceptable safety and tolerability of the drug in the parent study. The maintenance analyses are restricted to participants who had a response at entry, and the poster states that the analyses are descriptive.
  • Envudeucitinib exposure at week 48 differed by parent-study arm (48, 32, and 24 weeks), and the exposure-adjusted incidence rates are based on exposure in ONWARD3 only.
  • Week 48 PASI 90 and PASI 100 rates come from two analyses: a non-responder imputation analysis of 773 entrants (75% and 54%) and an integrated non-responder imputation analysis of 890 participants originally randomized to envudeucitinib (66% and 47%).
  • Enrollment is reported as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 by parent-study arm (poster).
  • The poster describes malignancies and serious infections as occurring at rates consistent with expected background rates without giving counts, and the report holds no ONWARD3 participant disposition beyond study entry.
  • The study is ongoing, with primary completion estimated for 2028-11.